logo

For the Inventor, By the Inventor

Mareil Marly, France

Philippe Bovy

This inventor holds 13 USPTO granted patents and 2 published patent applications. Top assignees: Sanofi-Aventis, Sanofi-Synthelabo, Synthelabo. Active years: 2000-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philippe Bovy. Retrieved from https://idiyas.com/inventor/philippe-bovy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 38.5

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 40(Granted Patents)


Company Filing History:

goldMedal9 out of 390 
 
Sanofi-Aventis
 patents
silverMedal3 out of 152 
 
Sanofi-Synthelabo
 patents
bronzeMedal1 out of 252 
 
Synthelabo
 patents

Years Active: 2000-2011

Loading Chart...
13 patents (USPTO):Explore Patents
1. 8063045 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2011-11-22),
2. 7659298 - Pyrazole derivatives and use thereof as orexin receptor antagonists (2010-02-09),
3. 7655663 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity (2010-02-02),
4. 7652021 - Compounds useful for DPP-IV enzyme inhibition (2010-01-26),
5. 7625929 - Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics (2009-12-01),
6. 7453010 - Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof (2008-11-18),
7. 7419974 - Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same (2008-09-02),
8. 7348327 - Compounds (2008-03-25),
9. 7030160 - Propanolaminotetralines, preparation thereof and compositions containing same (2006-04-18),
10. 6413984 - 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence (2002-07-02),
11. 6331549 - 1-aminoethylquinoline derivatives for treating urinary incontinence (2001-12-18),
12. 6200991 - Imidazole derivatives, preparation and therapeutic application thereof (2001-03-13),
13. 6063810 - 2-aminoethyl-benzofuran derivatives, preparation thereof and (2000-05-16),

Title: Philippe Bovy: Innovator in Pharmaceutical Chemistry

Introduction

Philippe Bovy is a notable inventor based in Mareil Marly, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of enzyme inhibitors and receptor antagonists. With a total of 13 patents to his name, Bovy's work has had a substantial impact on drug development.

Latest Patents

Among his latest patents, Bovy has developed fluoropyrrolidines that exhibit dipeptidyl peptidase enzyme inhibitory activity. This invention relates to new, potent DPP-IV enzyme inhibitors that contain fluorine atoms. Additionally, he has created pyrazole derivatives that serve as orexin receptor antagonists. This patent encompasses compounds that are effective in therapeutic applications, including their isomers, salts, and solvates.

Career Highlights

Philippe Bovy has worked with prominent companies in the pharmaceutical industry, including Sanofi-Aventis and Sanofi-Synthelabo. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug formulation.

Collaborations

Bovy has collaborated with several professionals in his field, including Peter Aranyi and Sandor Batori. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality of his inventions.

Conclusion

Philippe Bovy's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in drug development and therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…